Literature DB >> 7698891

Neurotoxicity of antitumoral IL-2 therapy: evoked cognitive potentials and brain mapping.

A Pace1, A Pietrangeli, L Bove, M Rosselli, M Lopez, B Jandolo.   

Abstract

Antitumoral interleukin-2 (IL-2) therapy is frequently associated with a neurotoxicity that manifests itself in neuropsychiatric disturbances and, more rarely, with neurological focal signs. With the aim of documenting the involvement of cognitive functions after IL-2 treatment, we studied 20 patients using evoked cognitive potentials (P300) and computer analysis of the EEG signal. A comparison of the tests performed before and after the subcutaneous infusion of IL-2 showed a significant lengthening in mean P300 latencies and a percentage increase in the EEG frequencies contained with the delta and theta bands, especially in the frontal regions.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7698891     DOI: 10.1007/bf02339930

Source DB:  PubMed          Journal:  Ital J Neurol Sci        ISSN: 0392-0461


  14 in total

1.  Acute fatal leukoencephalopathy after interleukin-2 therapy.

Authors:  C J Vecht; C Keohane; R S Menon; C J Punt; G Stoter
Journal:  N Engl J Med       Date:  1990-10-18       Impact factor: 91.245

2.  Neurological ischemic attack and interleukin-2 therapy.

Authors:  A Donnet; N Tubiana; O Chinot; P Juin
Journal:  Stroke       Date:  1991-06       Impact factor: 7.914

3.  Persistent neurotoxicity of systemically administered interferon-alpha.

Authors:  C A Meyers; R S Scheibel; A D Forman
Journal:  Neurology       Date:  1991-05       Impact factor: 9.910

4.  Differential central nervous system responses following single and multiple recombinant interleukin-2 infusions.

Authors:  M D Ellison; R J Krieg; J T Povlishock
Journal:  J Neuroimmunol       Date:  1990-08       Impact factor: 3.478

Review 5.  Central nervous system toxicity of interferons and other cytokines.

Authors:  V Bocci
Journal:  J Biol Regul Homeost Agents       Date:  1988 Jul-Sep       Impact factor: 1.711

Review 6.  Interleukin-2 toxicity.

Authors:  J P Siegel; R K Puri
Journal:  J Clin Oncol       Date:  1991-04       Impact factor: 44.544

7.  Transient focal neurologic deficits complicating interleukin-2 therapy.

Authors:  J T Bernard; S Ameriso; R A Kempf; P Rosen; M S Mitchell; M Fisher
Journal:  Neurology       Date:  1990-01       Impact factor: 9.910

8.  Neuropsychological and neurophysiological assessment of the central effects of interleukin-2 administration.

Authors:  A Caraceni; C Martini; F Belli; L Mascheroni; L Rivoltini; F Arienti; N Cascinelli
Journal:  Eur J Cancer       Date:  1993       Impact factor: 9.162

Review 9.  The P300 wave of the human event-related potential.

Authors:  T W Picton
Journal:  J Clin Neurophysiol       Date:  1992-10       Impact factor: 2.177

10.  Neuropsychiatric manifestations of human leukocyte interferon therapy in patients with cancer.

Authors:  F Adams; J R Quesada; J U Gutterman
Journal:  JAMA       Date:  1984-08-17       Impact factor: 56.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.